Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Bought by Silverarc Capital Management LLC

Silverarc Capital Management LLC grew its position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 9.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,171,847 shares of the company's stock after acquiring an additional 526,495 shares during the quarter. Gossamer Bio comprises about 1.2% of Silverarc Capital Management LLC's investment portfolio, making the stock its 27th largest holding. Silverarc Capital Management LLC owned about 2.72% of Gossamer Bio worth $5,583,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Smith Moore & CO. boosted its stake in Gossamer Bio by 32.7% during the 4th quarter. Smith Moore & CO. now owns 300,000 shares of the company's stock valued at $271,000 after purchasing an additional 74,000 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Gossamer Bio by 1.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company's stock valued at $1,123,000 after buying an additional 13,902 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Gossamer Bio by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company's stock worth $2,037,000 after buying an additional 38,084 shares during the period. Finally, Monaco Asset Management SAM grew its holdings in Gossamer Bio by 39.5% in the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company's stock worth $4,859,000 after buying an additional 1,520,721 shares in the last quarter. Institutional investors and hedge funds own 81.23% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on GOSS shares. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Gossamer Bio in a research note on Tuesday, March 18th. Wedbush restated an "outperform" rating and set a $4.00 price objective on shares of Gossamer Bio in a research note on Friday, March 14th. Finally, The Goldman Sachs Group decreased their target price on shares of Gossamer Bio from $8.00 to $7.00 and set a "buy" rating for the company in a research report on Thursday, April 17th.

Gossamer Bio Price Performance

NASDAQ GOSS traded down $0.02 on Friday, reaching $0.96. 2,464,392 shares of the stock traded hands, compared to its average volume of 1,577,818. Gossamer Bio, Inc. has a 12 month low of $0.50 and a 12 month high of $1.55. The company has a market cap of $217.75 million, a price-to-earnings ratio of -2.99 and a beta of 1.88. The firm's fifty day simple moving average is $1.10 and its 200 day simple moving average is $0.98. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its earnings results on Tuesday, March 18th. The company reported ($0.15) earnings per share for the quarter, meeting the consensus estimate of ($0.15). The firm had revenue of $9.38 million for the quarter, compared to the consensus estimate of $7.02 million. As a group, research analysts predict that Gossamer Bio, Inc. will post -0.28 EPS for the current fiscal year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.